Q-Line Biotech's high valuation raises concerns despite strong interim profits and growth prospects

Q-Line Biotech aims to raise over ₹214 crore through its IPO, but critics highlight concerns over its high valuation, financial stability, and limited peer comparison as it targets growth in the SME diagnostics market. Q-Line Biotech is coming to the…













